Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus abiraterone/prednisone versus abiraterone/prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer
NL-OMON60433Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apalutamide, abiraterone, prednisone and prednisolone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: completed.
02
Drugs
apalutamideabirateroneprednisoneprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60433.